Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease primarily affecting the joints resulting in their progressive destruction and in significant morbidity in the individual patient. Although the course of the disease is variable, the cumulative prevalence of work disability is as high as 50% at 10 years after onset of the disease (1). Considering that the prevalence of rheumatoid arthritis among adults has recently been estimated to be 10 per 1000 in the US, and that rheumatoid arthritis affects patients often in their most productive years, the socio-economic consequences for both the individual patient and society are severe (2).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
T.Sokka, H.Kautiainen, T.Mottonen, and P.Hannonen, Work disability in rheumatoid arthritis 10 years after the diagnosis, J Rheumatol. 26:1681 (1999).
R.C.Lawrence, C.G.Helmick, F.C.Arnett, R.A.Deyo, D.T.Felson, E.H.Giannini, S.P.Heyse, R.Hirsch, M.C.Hochberg, G.G.Hunder, M.H.Liang, S.R.Pillemer, V.D.Steen, and F. Wolfe, Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States, Arthritis Rheum. 41:778 (1998).
C.M.Weyand, New insights into the pathogenesis of rheumatoid arthritis, Rheumatology.(Oxford) 39 Suppl 1:3 (2000).
G.S.Firestein, Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?, Arthritis Rheum. 39:1781 (1996).
K.M.Hummel, P.K.Petrow, J.K.Franz, U.Muller-Ladner, W.K.Aicher, R.E.Gay, D.Bromme, and S.Gay, Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction, J Rheumatol. 25:1887 (1998).
T.Pap, Y.Shigeyama, S.Kuchen, J.K.Fernihough, B.Simmen, R.E.Gay, M.Billingham, and S.Gay, Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis, Arthritis Rheum. 43:1226 (2000).
G.Cunnane, O.FitzGerald, K.M.Hummel, R.E.Gay, S.Gay, and B.Bresnihan, Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis, Rheumatology.(Oxford) 38:34 (1999).
U.Muller-Ladner, J.Kriegsmann, B.N.Franklin, S.Matsumoto, T.Geiler, R.E.Gay, and S.Gay, Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice, Am J Pathol. 149:1607 (1996).
T.Geiler, J.Kriegsmann, G.M.Keyszer, R.E.Gay, and S.Gay, A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice, Arthritis Rheum. 37:1664 (1994).
C.Q.Chu, M.Field, S.Allard, E.Abney, M.Feldmann, and R.N.Maini, Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair, Br.J Rheumatol. 31:653 (1992).
B.Bresnihan and G.Cunnane, Interleukin-1 receptor antagonist, Rheum.Dis.Clin.North Am 24:615 (1998).
C.A.Dinarello, Biologic basis for interleukin-1 in disease, Blood 87:2095 (1996).
B.A.Moore, S.Aznavoorian, J.A.Engler, and L.J.Windsor, Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts, Biochim.Biophys.Acta 1502:307 (2000).
R.Horai, S.Saijo, H.Tanioka, S.Nakae, K.Sudo, A.Okahara, T.Ikuse, M.Asano, and Y.Iwakura, Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice, J Exp.Med. 191:313 (2000).
U.Muller-Ladner, C.R.Roberts, B.N.Franklin, R.E.Gay, P.D.Robbins, C.H.Evans, and S.Gay, Human IL-1Ra gene transfer into human synovial fibroblasts ischondroprotective, J Immunol. 158:3492 (1997).
M.Neidhart, R.E.Gay, and S.Gay, Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts, Arthritis Rheum. 43:1719 (2000).
T.Pap, W.H.van der Laan, K.R.Aupperle, R.E.Gay, J.H.Verheijen, G.S.Firestein, S.Gay, and M.Neidhart, Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis, Arthritis Rheum. 43:2531 (2000).
C.Q.Chu, M.Field, M.Feldmann, and R.N.Maini, Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis, Arthritis Rheum. 34:1 125 (1991).
J.Keffer, L.Probert, H.Cazlaris, S.Georgopoulos, E.Kaslaris, D.Kioussis, and G.Kollias, Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, EMBO J 10:4025 (1991).
L.A.Joosten, M.M.Helsen, F.A.van De Loo, and W.B.van Den Berg, Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra, Arthritis Rheum. 39:797 (1996).
A.F.Kavanaugh, Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis, Rheum.Dis.Clin.North Am 24:593 (1998).
M.Grell, H.Wajant, G.Zimmermann, and P.Scheurich, The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor, Proc.Natl.Acad.Sci.U.S.A 95:570 (1998).
B.W.Deleuran, C.Q.Chu, M.Field, F.M.Brennan, T.Mitchell, M.Feldmann, and R.N.Maini, Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha, Arthritis Rheum. 35:1170 (1992).
F.M.Brennan, D.L.Gibbons, A.P.Cope, P.Katsikis, R.N.Maini, and M.Feldmann, TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action, Scand.J Immunol. 42:158 (1995).
U.Muller-Ladner, C.H.Evans, B.N.Franklin, C.R.Roberts, R.E.Gay, P.D.Robbins, and S.Gay, Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model, Arthritis Rheum. 42:490 (1999).
D.M.Butler, M.Feldmann, F.Di Padova, and F.M.Brennan, p55 and p’75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts, Eur.Cytokine Netw. 5:441 (1994).
L.A.Joosten, M.M.Helsen, T.Saxne, F.A.van De Loo, D.Heinegard, and W.B.van Den Berg, IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation, J Immunol. 163:5049 (1999).
E.Keystone, J.Wherry, and P.Grint, IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis, Rheum.Dis.Clin.North Am 24:629 (1998).
C.Jorgensen, F.Apparailly, F.Canovas, C.Verwaerde, C.Auriault, C.Jacquet, and J.Sany, Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice, Arthritis Rheum. 42:678 (1999).
M.E.Stearns, F.U.Garcia, K.Fudge, J.Rhim, and M.Wang, Role of interleukin 10 and transforming growth factor betal in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice, Clin.Cancer Res. 5:711 (1999).
E.Neumann, M.Judex, T.Pap, O.Distler, R.E.Gay, P.D.Robbins, C.H.Evans, J.Schölmerich, S.Gay, and U.Muller-Ladner, Additive cartilage protection by retrovirus-based double gene transfer with IL-1ra and IL-10 in the SCID mouse model for RA, Arthritis Rheum. 43:S170 (2000).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Distler, O. et al. (2001). Gene transfer of protective cytokines in rheumatoid arthritis. In: Mackiewicz, A., Kurpisz, M., Żeromski, J. (eds) Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 495. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0685-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0685-0_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5194-8
Online ISBN: 978-1-4615-0685-0
eBook Packages: Springer Book Archive